title: Reversal of weightlessness-induced musculoskeletal losses with androgens: quantification by MRI.
abstract: Microgravity causes rapid decrement in musculoskeletal mass is associated with a marked decrease in circulatory testosterone levels, as we reported in hindlimb-suspended (HLS) rats. In this model which simulates microgravity, we hypothesized that testosterone supplementation should prevent these losses, and we tested this in two studies. Muscle volumes and bone masses were quantitated by using magnetic resonance imaging (MRI) on day 12. In the first study, 12-wk-old Sprague-Dawley rats that were HLS for 12 days lost 28.5% of muscle volume (53.3 +/- 4.8 vs. 74.5 +/- 3.6 cm3 in the ground control rats; P < 0.001) and had a 5% decrease in bone mineral density (BMD) (P < 0.05). In the second study, 30 male 12-wk-old Wistar rats were HLS and were administered either a vehicle (control), testosterone, or nandrolone decanoate (ND). An additional 20 rats were used as ground controls, one-half of which received testosterone. HLS rats had a significant reduction in muscle volume (42.9 +/- 3.0 vs. 56 +/- 1.8 cm3 in ground control rats; P < 0.01). Both testosterone and ND treatments prevented this muscle loss (51.5 +/- 2 and 51.6 +/- 1.2 cm3, respectively; a 63% improvement; P < 0. 05). There were no statistical differences between the two active treatment groups nor with the ground controls. Similarly, there was an 85% improvement in BMD in the testosterone group (1.15 +/- 0.04 vs. 1.04 +/- 0.04 density units in vehicle controls; P < 0.05) and a 76% improvement in the ND group (1.13 +/- 0.07 density units), whereas ground control rats had a BMD of 1.17 +/- 0.03 density units. Because serum testosterone levels are markedly reduced in this model of simulated microgravity, androgen replacement seems to be a rational countermeasure to prevent microgravity-induced musculoskeletal losses.
authors.affiliation: Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas 77555-1065, USA. swimalaw@utmb.edu
authors.forename: S M
authors.initials: SM
authors.lastname: Wimalawansa
authors.forename: M T
authors.initials: MT
authors.lastname: Chapa
authors.forename: J N
authors.initials: JN
authors.lastname: Wei
authors.forename: K N
authors.initials: KN
authors.lastname: Westlund
authors.forename: M J
authors.initials: MJ
authors.lastname: Quast
authors.forename: S J
authors.initials: SJ
authors.lastname: Wimalawansa
mesh_terms: D045930:Anabolic Agents / Q000494:pharmacology; D000728:Androgens / Q000494:pharmacology*; D000818:Animals; D001835:Body Weight / Q000502:physiology; D001842:Bone and Bones / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology*; D019417:Hindlimb Suspension / Q000502:physiology*; D008279:Magnetic Resonance Imaging; D008297:Male; D018482:Muscle, Skeletal / Q000033:anatomy & histology / Q000187:drug effects / Q000502:physiology*; D009277:Nandrolone / Q000031:analogs & derivatives / Q000494:pharmacology; D000077603:Nandrolone Decanoate; D051381:Rats; D017207:Rats, Sprague-Dawley; D014893:Weightlessness / Q000009:adverse effects*
chemical_list: D045930:Anabolic Agents; D000728:Androgens; D009277:Nandrolone; D000077603:Nandrolone Decanoate